论文部分内容阅读
嵌合抗原受体自然杀伤细胞（CAR-NK）免疫治疗技术是一种新型抗肿瘤免疫方法。NK细胞可来源于外周血、脐带血、NK-92细胞系及诱导多能干细胞。CAR-NK细胞可非特异性识别靶抗原且无人类白细胞抗原限制性，异体输注不会引起移植物抗宿主病，对白血病、淋巴瘤及多发性骨髓瘤的原代细胞及动物模型具有较强的抗肿瘤效应，作为现货型产品在临床中具有广泛的应用前景。对CAR-NK载体构建及其在血液肿瘤中的临床初步应用和面临的挑战进行综述。“,”Chimeric antigen receptor natural killer cell (CAR-NK) is a new promising immunotherapy. NK cell can derive from peripheral blood cells, cord blood cells, NK-92 cell line and iPSC cells. CAR-NK cells can recognize target antigens non-specifically and are not restricted by human leukocyte antigens. Allogeneic infusion of CAR-NK cells does not cause graft-versus-host disease. It has a strong effect on primary cells of leukemia, lymphoma and multiple myeloma, thus making animal models have strong anti-tumor effect. Therefore, as a “off-the-shelf” product, CAR-NK cells have a wide range of clinical applications. In this paper, the construction of CAR-NK vector and its preliminary clinical application in hematological tumors and the challenges were reviewed.